Immune Humanized Platforms for Preclinical Evaluation of Tumor Efficacy & Cytokine Release Mediated Toxicity

Time: 12:00 pm
day: Day One


• Human PBMC engraftment in MHC deficient recipients diminishes acute GvHD
• Accurate modeling of treatment induced human cytokine release in vivo
• Human donor specific differences in efficacy & toxicity for drug candidate selection